Goldman SachsGSPAST TOP PICKNov 28, 2017Stock price when the opinion was issued
As of Jul 13, 2026. Market Open.
Different businesses. LLY is a big play in GLP-1 drugs. How will pills effect the injections business? LLY has done a good job of navigating these new pills. GS enjoys increased stock market and IPO businesses. He prefers LLY, which is tied to a secular growth trend, but GS' good times in capturing revenue in this cycle will end.
Mergers are increasing, and banks like GS makes advisory fees from them. Also, the banks have been rallying since oil slumped, and will benefit further from rising interest rates, which appears will happen later this year. Plus, hyperscalers may need to keep borrowing money to keep competing with each other.
Among the leaders in the M&A world. Under the Trump administration, M&A activity is way up due to less regulation. Impeccably well positioned to keep driving forward.
Core holding. Buying today for new clients. For his firm, have to see 10% annualized return over 5 years to justify holding or buying a stock. And this name fits. Stock's not as cheap as 5 years ago, so growth will be slower going forward.
(A Top Pick Aug 8/16. Up 47%.) All global investment banks are benefiting as interest rates start to rise. This one has done what almost no one else has done, which is not reducing exposure to the riskier trading parts of the business. Their global footprint is almost 2nd to none today. They have good exposure in Europe, whose economy is slowly recovering.